A61P 13 - Drugs for disorders of the urinary system

Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2002
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156067 New drug combinations
10/24/2002	US20020156050 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors
10/24/2002	US20020156036 Expression vector encoding a fusion protein with segments of a region which binds to an epitope or fragment and fragment or whole proteins that can cross the blood brain barrier
10/24/2002	US20020156027 Ketolide antibiotics
10/24/2002	US20020156001 Novel fibroblast growth factor ( FGF23) and methods for use
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155992 Paclitaxel, epipodophyllotoxin, decetaxel, topotecan, and podophyllotoxin covalently conjugated to a polypeptide drug carrier having 50-90% by weight glutamic acid; inproved solubility
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155168 Use of rare earth compounds for the prevention of kidney stone disease
10/24/2002	CA2490819A1 Compounds useful as anti-inflammatory agents
10/24/2002	CA2444761A1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
10/24/2002	CA2444632A1 Vascular endothelial growth factor 2
10/24/2002	CA2444596A1 Large conductance calcium-activated k channel opener
10/24/2002	CA2444481A1 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
10/24/2002	CA2444455A1 N-biphenylcarbonyl- and n-phenylpyridylcarbonyl substituted bi- and tricyclic azepines and diazepines as vasopressing agonists
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2443995A1 Endothelial cell expression patterns
10/24/2002	CA2443910A1 Novel use of arylethenesulfonamide derivatives
10/24/2002	CA2443870A1 Cyclohexylphenyl vasopressin agonists
10/24/2002	CA2443699A1 Phenyl heterocyclyl ether
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/24/2002	CA2443565A1 Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2443052A1 Use of cationic dextran derivatives for protecting dose-limiting organs
10/24/2002	CA2438107A1 G-protein coupled receptor molecules and uses thereof
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251177A2 Cytokine-, stress-, and oncoprotein-activited human protein kinase kinases
10/23/2002	EP1251137A2 Use of insulin-like growth factor agonist peptides
10/23/2002	EP1251128A1 Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists
10/23/2002	EP1250849A1 Morinda citrifolia (Noni) enhanced animal food product
10/23/2002	EP1250355A1 Chimeric prostate-homing peptides with pro-apoptotic activity
10/23/2002	EP1250328A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
10/23/2002	EP1250144A1 Vegetable oil for preparing a composition inhibiting 5$g(a)- reductase activity
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP1250139A1 Product for treating gynecomastia
10/23/2002	EP1250116A1 Pharmaceutical and cosmetic carrier or composition for topical application
10/23/2002	EP1066297B1 Phosphinic acid derivatives
10/23/2002	EP0894089B1 Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
10/23/2002	EP0626845B1 Improved amino acid solutions for treatment of peritoneal dialysis patients
10/23/2002	CN1376160A Novel macrolide antibiotics
10/23/2002	CN1376156A Benzodiazepin derivatives, the production and use thereof
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1376067A Conditioned cell culture medium compositions and method of use
10/23/2002	CN1375304A Chinese medicine specially for treating prostatosis
10/23/2002	CN1093128C Process for preparing eprosartan
10/22/2002	US6469174 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
10/22/2002	US6469058 For the treatment of nonsmall cell lung cancer
10/22/2002	US6469056 Pharmaceutically active compounds, their preparation and use as ECE-inhibitors
10/22/2002	US6469037 Prophylactic or therapeutic drug for renal diseases
10/22/2002	US6469036 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/22/2002	US6469032 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
10/22/2002	US6469024 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
10/22/2002	US6469018 Compounds
10/22/2002	US6469012 Pyrazolopyrimidinones for the treatment of impotence
10/22/2002	US6469007 P-substituted-n-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl) -piperazin-1-yl)-propyl)-n-pyridin-2-yl-benzamide,
10/22/2002	US6468975 Glucocorticoid receptor antagonists that are preferably liver selective and are useful in treatment of diabetes
10/22/2002	US6468960 Therapeutic compositions and methods for enhancing angiogenesis
10/22/2002	US6468756 Methods of identifying compounds that bind to SNORF25 receptors
10/22/2002	CA2106954C Dry starch-iodine pharmaceutical formulations
10/17/2002	WO2002081728A2 Quinoline inhibitors of hyak1 and hyak3 kinases
10/17/2002	WO2002081668A2 Desaturase genes and uses thereof
10/17/2002	WO2002081521A2 Osteoprotegerin in milk
10/17/2002	WO2002081508A2 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	WO2002081477A1 7-substituted morphinane derivatives and medicinal use thereof
10/17/2002	WO2002081467A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
10/17/2002	WO2002081463A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002	WO2002081461A1 Piperazine derivatives as tachykinin antagonists
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081420A1 Cyclooctanone derivative and cyclodecanone derivative, and use thereof
10/17/2002	WO2002081398A2 Additives for building industry obtained from by-products and process for their production
10/17/2002	WO2002081020A2 Method for preventing acute renal failure
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002	WO2002080935A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/17/2002	WO2002080930A1 Intermittent lowering of levels of cortisol and other adrenalhormones as treatment of clinical conditions associated with abnormal concentrations of such hormones in man and animals
10/17/2002	WO2002080929A1 Remedies or preventives for interstitial nephritis
10/17/2002	WO2002080927A1 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080924A1 Novel use of arylethene sulfonamide derivative
10/17/2002	WO2002080918A1 Remedial or prophylactic agent for frequent urination or urinary incontinence
10/17/2002	WO2002080905A1 Kappa opiate agonists for the treatment of bladder diseases
10/17/2002	WO2002080903A1 Functional role for cannabinoids in autonomic stability during sleep
10/17/2002	WO2002080854A2 Compositions and methods for the prevention and treatment of human prostate cancer
10/17/2002	WO2002080754A2 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002	WO2002080676A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002	WO2002062301A3 Method and composition for rejuvinating cells, tissues, organs, hair and nails
10/17/2002	WO2002057261A3 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
10/17/2002	WO2002043567A3 A method of treating cancer
10/17/2002	WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002	WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002	WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002	WO2002029061A3 G-protein coupled receptors
10/17/2002	WO2002010192A9 Somatostatin analogues
10/17/2002	WO2001098323A3 G-protein coupled receptors
10/17/2002	WO2001077378A3 Diagnosis of diseases associated with dna adducts

1 ... 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 ... 562